Journal
CELL STEM CELL
Volume 4, Issue 4, Pages 313-323Publisher
CELL PRESS
DOI: 10.1016/j.stem.2009.02.013
Keywords
-
Categories
Funding
- German Research Foundation [DFG TH1398/2-1]
- Ludwig Maximilians University Munich
- German Research Foundation
Ask authors/readers for more resources
Ischemic cardiomyopathy is one of the main causes of death, which may be prevented by stem cell-based therapies. SDF-1 alpha is the major chemokine attracting stem cells to the heart. Since SDF-1 alpha is cleaved and inactivated by CD26/dipeptidylpeptidase IV (DPP-IV), we established a therapeutic conceptapplicable to ischemic disorders in general-by combining genetic and pharmacologic inhibition of DPP-IV with G-CSF-mediated stem cell mobilization after myocardial infarction in mice. This approach leads to (1) decreased myocardial DPP-IV activity, (2) increased myocardial homing of circulating CXCR-4(+) stem cells, (3) reduced cardiac remodeling, and (4) improved heart function and survival. Indeed, CD26 depletion promoted post-translational stabilization of active SDF-1 alpha in heart lysates and preserved the cardiac SDF-1-CXCR4 homing axis. Therefore, we propose pharmacological DPP-IV inhibition and G-CSF-based stem cell mobilization as a therapeutic concept for future stem cell trials after myocardial infarction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available